PlexusDx provides tirzepatide compounded by licensed 503A pharmaciesnot FDA-approved formulations
The dominance of this segment is primarily attributed to the growing demand for complexion enhancement, pigmentation reduction, and non-surgical cosmetic procedures among consumers
PlexusDx's precision-wellness model helps identify who may benefit from proactive biomarker monitoring rather than assuming a one-size-fits-all approach
My sense is, and we've come up with this recognition, that we think the competing effects of improved cardiovascular health and reduced cardiovascular death and slowing progression of CKD is going to build the population of patients that have CKD, advanced CKD as a substrate over time and that its overall impact on our population today with what we know looks to be either neutral or slightly positive over the long term
But with GLP-1 popularity rising, the stakes are higher
[DOI] [PubMed] [Google Scholar] 6.DiFeliceantonio AG & Small DM Nature Neurosci